Clinical trial
A Phase 2b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine)
NCT05148871 is registered in ClinicalTrials.gov with Vaxine Pty Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine)
- Lead sponsor
- Vaxine Pty Ltd
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- March 1, 2022
- Completion date
- October 6, 2024
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.